The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Death, Hospitalization, and Economic Associations among Incident Hemodialysis Patients with Hematocrit Values of 36 to 39%
Abstract
Anemia treatment with epoetin has led to dramatic increases in hematocrit levels since 1989. Studies have demonstrated that morbidity and mortality rates are lower when hematocrit values are within the Disease Outcomes Quality Initiative (DOQI) target range (33 to 36%). Recently, clinical studies demonstrated that patients without cardiovascular disease exhibited lower morbidity rates and improved cognitive function with hematocrit values of >36%. One prospective trial, in contrast, demonstrated that normal hematocrit values among patients with cardiac disease were associated with higher mortality rates. These conflicting results have led to concerns regarding the risks and benefits associated with hematocrit values between 36 and 42%. To address these concerns, a recent cohort of 1996 to 1998 incident hemodialysis patients was studied, with assessments of the risks of death and hospitalization and the medical costs associated with hematocrit values of >36%. Patients survived at least 9 mo after dialysis initiation, and comorbidity, disease severity, and hematocrit levels were determined for months 4 to 9. Patients were grouped on the basis of hematocrit values, i.e., <30, 30 to <33, 33 to <36, 36 to <39, or > or =39%, with 1 yr of follow-up monitoring. A Cox regression model was used to evaluate all-cause and cause-specific mortality and hospitalization rates. The economic evaluations included analyses with Medicare Parts A and B allowable expenditures as the dependent variable and the same clinical characteristics as independent variables. For patients with hematocrit values of > or =36%, mortality rates were not different, hospitalization rates were 16 to 22% lower, and expenditures were 8.3 to 8.5% less, compared with patients with hematocrit values of 33 to <36%. These observations do not demonstrate causality. Additional long-term studies are needed to assess the risks of higher hematocrit values among all patients and patients with cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Smearing Estimate: A Nonparametric Retransformation Method
Duan, N. (1983) · Journal of the American Statistical Association · doi:10.1080/01621459.1983.10478017 · Cited by 2,232
The logged dependent variable, heteroscedasticity, and the retransformation problem
Manning, W. G. (1998) · Journal of Health Economics · doi:10.1016/s0167-6296(98)00025-3 · Cited by 877
Self-citationHematocrit Level and Associated Mortality in Hemodialysis Patients
MA, J. Z., EBBEN, J., XIA, H., & COLLINS, A. J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v103610 · Cited by 577
Self-citationHEALTH CARE FINANCING ADMINISTRATION: <http://www.hcfa.gov>
Editorial Submission, H. (2000) · Health Care on the Internet · doi:10.1300/j138v04n01_15 · Cited by 532
MORENO, F., SANZ-GUAJARDO, D., LÓPEZ-GÓMEZ, J. M., JOFRE, R., & VALDERRÁBANO, F. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v112335 · Cited by 254
Normalizing hematocrit in dialysis patients improves brain function
Pickett, J. L., Theberge, D. C., Brown, W. S., Schweitzer, S. U., & Nissenson, A. R. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70150-2 · Cited by 250
Hematocrit Levels and Hospitalization Risks in Hemodialysis Patients
XIA, H., EBBEN, J., MA, J. Z., & COLLINS, A. J. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1061309 · Cited by 243
Self-citationKhan, S., & Pereira, B. J. G. (2000) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2000.00036.x · Cited by 158
Cooper, E. B. (2000) · Perspectives on Fluency and Fluency Disorders · doi:10.1044/ffd10.1.6 · Cited by 123
Trends in anemia treatment with erythropoietin usage and patient outcomes
Collins, A. J., Ma, J., Xia, A., & Ebben, J. (1998) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(98)70176-3 · Cited by 95
Self-citation
Cited by
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Tonelli, M., Sacks, F., Arnold, M., Moye, L., Davis, B., & Pfeffer, M. (2008) · Circulation · doi:10.1161/circulationaha.107.727545 · Cited by 816
Transfusion medicine: looking to the future
Goodnough, L. T., Shander, A., & Brecher, M. E. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12195-2 · Cited by 291
Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin
Fishbane, S., & Berns, J. S. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00532.x · Cited by 289
Metadata
- Authors
- COLLINS, A. J., LI, S., PETER, W. S., EBBEN, J., ROBERTS, T., MA, J. Z., & MANNING, W.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2001-11
- Volume
- 12
- Issue
- 11
- Pages
- 2465-2473
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2107215009
- Cited by
- 302
- References
- 12
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Death, Hospitalization, and Economic Associations among Incident Hemodialysis Patients with Hematocrit Values of 36 to 39%. https://app.cochat.ai/papers/10.1681/asn.v12112465
- The paper
- COLLINS, A. J., LI, S., PETER, W. S., EBBEN, J., ROBERTS, T., MA, J. Z., & MANNING, W. (2001). Death, Hospitalization, and Economic Associations among Incident Hemodialysis Patients with Hematocrit Values of 36 to 39%. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.v12112465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.